Antidote Health Launches Telemedicine Service for Prediabetes and Type 2 Diabetes – Yahoo Finance

Led by endocrinologist and diabetes specialist Dr. Lyle Mitzner, the new service addresses the soaring diabetes epidemic in the U.S. and underscores Antidote Health’s commitment to ensure everyone has access to affordable, high-quality healthcare.
NEW YORK, November 17, 2022–(BUSINESS WIRE)–Antidote Health, a telehealth company that views accessible, affordable healthcare as a fundamental human right, is proud to announce the launch of its new service for prediabetes and type 2 diabetes care. Led by Dr. Lyle Mitzner, the comprehensive service addresses the soaring diabetes epidemic in the U.S. and underscores Antidote Health’s commitment to ensure everyone has access to affordable high-quality healthcare, no matter their race, location or circumstance.
"Diabetes is now the seventh leading cause of death in the U.S.," says Antidote Health Co-founder and CEO Avihai Sodri. "In addition to our services for primary, mental health and hypertension care, we are proud to take another step towards affordable healthcare. This new service is critical given that many Americans with diabetes or prediabetes have lower income and lack adequate access to care. These factors, particularly cost and access, should never present barriers to healthcare. By providing a personalized experience from a designated doctor from assessment and diagnoses to treatment plans, prescriptions and monitoring, Antidote Health offers affordable, convenient, high-quality care for all."
The number of U.S. adults diagnosed with diabetes has more than doubled in the last 20 years. According to the CDC, an estimated 37 million Americans have diabetes, with type 2 accounting for approximately 90% to 95% of all diagnosed cases. Further, about 86 million adults are not aware of the fact they have prediabetes. The CDC’s latest National Diabetes Statistics Report states that the highest prevalence is in adults with a family income below the federal poverty line and within minority groups. Considering that medical costs for people with diabetes are twice as high in comparison to those without diabetes, there has never been a more important time to offer affordable and easily accessible telemedicine care.
"Adults with diabetes are often at an increased risk for other diseases such as high blood pressure, eye disease, kidney disease and cardiovascular disease," says Dr. Mitzner, an esteemed endocrinologist who has been in clinical practice for more than 20 years at the Joslin Diabetes Center in Boston, MA. "With early screening, treatment and education, individuals with prediabetes and those with type 2 diabetes can live long, healthy, and productive lives. Telemedicine, which has truly been lifesaving during the ongoing pandemic, can bridge the ever-widening healthcare gap in the U.S. that disproportionately impacts low-income and minority groups."
"Care for All" is not just a nice feel-good tagline—it’s Antidote Health’s purpose and ethos. Antidote Health offers a state-of-the-art telehealth platform that provides affordable one-time or on-going health services enabling on-demand access and chronic care management from one’s home, workplace or other locations, with little to no waiting time.
Antidote Health’s primary, mental health, hypertension and diabetes care services are supported by some of healthcare’s foremost physicians, as well as internationally known celebrities like Giannis Antetokounmpo. One of the world’s most admired professional basketball players, Giannis is both an ambassador and investor in Antidote Health.
About Antidote Health
Antidote Health, a leading telehealth company, believes healthcare is a fundamental human right. Our services democratize access, delivering care for individuals or the whole family. We work with individuals, businesses of any size, non-profits. Our goal is to ensure that everyone has affordable, high-quality acute, primary and chronic care services, 24/7/365. For more information visit: www.antidotehealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005174/en/
Contacts
Valerie Christopherson
Andrew Ellison
GRC for Antidote Health
Antidote@globalresultspr.com
Hundreds of Americans die each day from COVID — and the unvaccinated make up a majority of those dead and hospitalized.
Shares of Provention Bio Inc. were down 3.9% in trading on Friday morning, the day after the Food and Drug Administration approved the company's treatment that can delay the onset of Type 1 diabetes in some patients. The intravenous therapy, Tzield, can delay the onset of Stage 3 Type 1 diabetes in patients with Stage 2 Type 1 diabetes. Stage 3 is usually when patients are diagnosed with Type 1 diabetes. "It cannot be emphasized enough how precious a delay in the onset of Stage 3 T1D can be from
The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.
Inovio is discontinuing development of its vaccine product candidates targeting Lassa Fever and Middle East Respiratory Syndrome, or MERS, the latest setback for the Montgomery County biotechnology company. Inovio said it agreed with its collaborator, the Coalition for Epidemic Preparedness Innovations (CEPI), to stop work on both experimental products, INO-4500 and INO-4700, following initial analyses of data from studies testing the effectiveness of each.
The FDA is asking the drug development outfit for more information regarding its tumor-infiltrating lymphocyte therapy.
Investors know that the key to profits is in the return – and that means, a willingness to shoulder risk. Risk is relative, of course, and tends to run hand-in-hand with the return potential. Find a stock with a giant return potential, and chances are, you’ve also found one with a higher risk profile. The highest returns usually come along with the lowest share prices. After all, when a stock is priced for just pennies, even a small gain in share price translates into a huge return. Which means
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) a leader in cannabinoid-derived drug discovery and development is providing its shareholders with a regulatory status update on the REDUVO™ New Drug Submission (NDS).
Investing in biotech companies, especially relatively small ones, can be a double-edged sword. With that in mind, let's look at two gene-editing-focused biotechs that could perform substantially better next year: CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). Right now, CRISPR Therapeutics is a clinical-stage biotech.
Rockville’s MacroGenics Inc. (NASDAQ: MGNX) just had its second big win within a month, after inking a major deal with a U.S. pharmaceutical company in October. MacroGenics said late Thursday the Food and Drug Administration has approved teplizumab, a Type 1 diabetes treatment candidate that Provention Bio Inc. bought from MacroGenics in 2018. As part of that deal, Red Bank, New Jersey's Provention agreed to pay $60 million to Macrogenics upon receiving the agency’s green light to take the drug to market.
Apellis Pharmaceuticals said Friday the Food and Drug Administration will review its new eye-disease drug in February, and APLS stock surged.
Pfizer and BioNTech said the immune response generated by their bivalent COVID-19 booster showed strong results against the newer omicron sublineages.
Operation Warp Speed, the Trump-era program that poured billions of dollars into developing COVID shots, seemed to signal a new dawn of American vaccine making, demonstrating how decades of scientific grunt work could be turned into lifesaving medicine in a matter of months. But as a third pandemic winter begins in the United States, its vaccine-making effort has lost steam. Efforts to test and produce next-generation COVID vaccines are bogged down by bureaucratic problems and funding shortfalls
Editas (EDIT) pauses enrollment in the phase I/II BRILLIANCE study evaluating EDIT-101 for treating blindness due to Leber congenital amaurosis 10. Stock falls.
Biotech giant Gilead (GILD) outperforms the industry and the S&P 500 Index as its core business maintains momentum despite volatility.
Intra-Cellular Therapeutics (ITCI) currently has only one marketed product in its portfolio, Caplyta, approved for schizophrenia and bipolar disorders. The company is evaluating the candidate in several other indications.
Shares of Editas Medicine (NASDAQ: EDIT) were down as much as 21% at one point on Thursday. Editas has a 52-week low of $9.59 and a 52-week high of $37.50, and is down more than 60% so far this year. The clinical-stage biotech, which seeks therapies through CRISPR gene-editing, paused its Brilliance Phase 1/2 trial for its lead therapy, EDIT-101, to treat the rare eye disease, leber congential amaurosis (LCA) 10, that affects the retina.
By John Vandermosten, CFA NASDAQ:NOVN READ THE FULL NOVN RESEARCH REPORT Third Quarter 2022 Results On November 14, 2022, Novan Inc. (NASDAQ:NOVN) reported third quarter financial and operational results in a press release and the filing of Form 10-Q . A conference call and webcast were subsequently held to update investors on recent developments. The call highlighted the performance of the EPI
Iovance Biotherapeutics Inc (NASDAQ: IOVA) announced that its ongoing rolling Biologics License Application (BLA) submission to the FDA for lifileucel is expected to be completed in the first quarter of 2023 as against Q4 FY22 expected earlier. As part of an amendment to the ongoing investigational new drug application submitted during Q3, Iovance received recent FDA feedback regarding supplemental assay validation information and comparability data for lifileucel. Iovance will address these FDA
Immunic Inc (NASDAQ: IMUX) has reported newly available data from its phase 2 EMPhASIS trial of lead asset, vidofludimus calcium (IMU-838), in relapsing-remitting multiple sclerosis (RRMS). During the 24-week treatment period, 12-week and 24-week Confirmed Disability Worsening (12w/24wCDW) events occurred in 1.6% of subjects in the combined vidofludimus calcium treatment arms as compared to 3.7% in the placebo group. Related: Immunic's Early Cut Data From Psoriasis Candidate Failed To Show Desir
Few illnesses instill as much fear as Alzheimer's, a fatal neurodegenerative disease that destroys memory and identity. The dread is compounded by the uncertainty that often surrounds the diagnosis of the most common form of dementia. Brain autopsies remain the only way to know for sure whether someone had the disease, which the Centers for Disease Control and Prevention estimates affects 6.5 million people in the United States. Over the past several years, sophisticated tests such as spinal tap

source